language
2026-07-08
Iongen Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of IG001119 for the Treatment of Pain
2026-01-07
China Market: Opioids Under Strict Regulation & Vast Unmet Clinical Needs
Per the China Pain Medicine Development Report (2020), the number of chronic pain patients in China exceeds 300 million, with an annual increase of 10–20 million.
2026-01-07
Global Market: Globally, 1 in 5 people suffers from chronic pain.
According to Mordor Intelligence, the global pain management market is projected to reach 78.12 billion in 2024 and expand to 93.19 billion by 2029, growing at a CAGR of 3.59% during the forecast period(2024-2029).
U.S. Market: Enduring the Opioid Crisis & Largest Pain Management Market
Currently, in the U.S. >17M Americans experience high intensity chronic pain. For acute pain, Vertex estimates that there are ~1.5B analgesic days/year.
07
2026/01
公司于2026年1月11日前往美国旧金山参加第九届BFC医疗健康国际商务合作投资研讨会。
06
2026/01
Neurology is back. A suite of high profile approvals — from Biogen and Eli Lilly’s Alzheimer’s disease drugs to Bristol Myers Squibb’s schizophrenia treatment Cobenfy (xanomeline and trospium chloride) and, most recently, Vertex Pharmaceuticals’ non-opioid pain treatment Journavx (suzetrigine) — has placed the category firmly back onto dealmakers’ radars.
02
2026/01
• Initiate 3 IND-enabling studies
• Further strengthen the team and enhance corporate R&D capabilities
• Initiate Series A fundraising and BD engagements
12
2025/11
• Focus on pain management
• Completed Pre-A round financing
12
2025/11
• Strengthened organizational capacity
• Pipeline milestones progressing as planned
• Awarded “Technology-based SME title"
12
2025/11
• Successfully closed an angel funding round raising tens of millions RMB
• State-of-the-art lab facility operational
• Core R&D programs launched
12
2025/11
• Company incorporated
• Core team established with drug discovery expertise
12
2025/11
Want more product service? Leave us a message
We will contact you within one working day. Please pay attention to your email.